ASCO and CAP Guidelines for HER2 Testing
Below, find the clinical practice guideline update from ASCO and CAP (October 2013) on Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Dako recommends that laboratories follow the instructions described in the package insert for the FDA-approved kit. Following other guidelines than those recommended in the package insert is on the discretion of the lab director.
Symposium on Challenges in Breast Cancer
During September 2014, Agilent Technologies conducted an industry symposium at the ECP. The symposium was entitled "Current Challenges in Breast Cancer Diagnostics: New Guidelines and Implementation in Clinical Practice".
See two of the speakers talk about the ASCO/CAP guidelines in practice and about navigating the changing HER2 testing guidelines.
Implementation of ASCO/CAP Guidelines in Clinical Practice
Ian Ellis, Professor of Cancer Pathology, Nottingham University, talks about the UK’s new imminent guidelines, the similarities and differences from the latest ASCO/CAP guidelines.